Evidence map›Paper›PMID 19648822›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2009

Increased risk of genital ulcer disease in women during the first month after initiating antiretroviral therapy.

Susan M Graham, Linnet Masese, Ruth Gitau, Dickson Mwakangalu, Walter Jaoko, Jeckoniah Ndinya-Achola, Kishor Mandaliya, Norbert Peshu, Jared M Baeten, R Scott McClelland

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. 2024 European guidelines for the management of genital herpes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Susan M GrahamDepartments of Medicine, Epidemiology and Global Health, University of Washington, Seattle, WA 98104-2499, USA. grahamsm@u.washington.edu
Linnet Masese
Ruth Gitau
Dickson Mwakangalu
Walter Jaoko
Jeckoniah Ndinya-Achola
Kishor Mandaliya
Norbert Peshu
Jared M Baeten
R Scott McClelland
University of Nairobi · KEUniversity of Washington · USKenya Medical Research Institute · KEUniversity of Toronto · CA

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Judith Tsui · 1988 to 2026
$104.9M
Antiretroviral Therapy and HIV-1 Infectivity in WomenR01AI058698 · NIAID · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, RAYMOND SCOTT · 2005 to 2010
$2.8M
Genital HIV-1 Shedding among Women Starting Second-Line Antiretroviral TherapyK23AI069990 · NIAID · UNIVERSITY OF WASHINGTON · PI GRAHAM, SUSAN MARIE · 2006 to 2010
$633k
NIAID NIH HHS K23 AI069990NIAID NIH HHS K23 AI69990NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI 27757NIAID NIH HHS R01 AI058698
6 · The paper itself

Abstract

introductionGenital ulcer disease (GUD) is common in HIV-1-infected women, and a small number of studies have suggested increased GUD risk after antiretroviral therapy (ART) initiation. To better define this risk, we monitored 134 women at ART initiation and monthly thereafter.

methodsWomen were evaluated monthly for genital ulcers. Syphilis serology was tested quarterly, and chancroid culture was performed on ulcers that were felt to be clinically consistent with a diagnosis of chancroid. A logistic model with generalized estimating equations was used to analyze predictors of GUD from baseline until 6 months after ART initiation.

resultsDuring the study period, GUD occurred in 54 women (40.3%) at 85 visits (10.0%). GUD prevalence was 9.7% at baseline, increased to 16.7% at month 1 [adjusted odds ratio (aOR) 1.9 (1.0-3.6), P = 0.04], then decreased to 6.4% by month 6. History of GUD [aOR 3.8 (1.9-7.7), P < 0.001) and CD4 count <100 [aOR 1.8 (1.0-3.4), P = 0.06] were associated with increased risk of GUD after ART initiation. DISCUSSION: Women experience increased risk of GUD in the first month after ART initiation, particularly if they have low CD4 counts or a history of GUD.

Indexed as

HIV-1Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesFemaleGenital Diseases, FemaleHIV InfectionsHumansKenyaPrevalenceRisk FactorsUlcerAnti-HIV Agents

Identifiers

PMID19648822
PMCPMC2787852
OpenAlexW2023728019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.